Albany, NY -- (SBWIRE) -- 02/20/2019 -- Systemic Lupus Erythematosus (SLE) - Market and Epidemiology Report

20 Feb. 19

The total number of prevalent cases of SLE in 2016 were found to be approximately 5,70,000 in the 7MM.

1. Among the EU5 countries, the United Kingdom had the highest prevalent population of SLE, followed by Italy, in 2016.
2. Spain had the lowest prevalent population of SLE in 2016.
3. Lupus nephritis (LN) is a severe manifestation of SLE that causes dramatic morbidity and mortality. The LN was highly prevalent in the United States in 2016.

(Albany, US) DelveInsight launched Systemic Lupus Erythematosus (SLE) - Market Insights, Epidemiology and Market Forecast- 2028

Key topics covered

1. The Systemic Lupus Erythematosus market report will help to develop Business Strategies by understanding the trends shaping and driving the Systemic Lupus Erythematosus market.
2. The Systemic Lupus Erythematosus market organize sales and marketing efforts by identifying the best opportunities.
3. To understand the future market competition in the Systemic Lupus Erythematosus market.

Request for sample pages

"Male-to-female ratios of Systemic Lupus Erythematosus patients differ among various countries, but female excess is a consistent finding."

Despite of improvements in the treatment methodologies for Systemic Lupus Erythematosus (SLE) during the last few years, a complete cure seems to be beyond the horizon. Notably, relapsing manifestations and complications of past treatments still remain as important markers of morbidity. While lupus cannot be cured, it can however be controlled. The corresponding treatment involves monitoring the condition, preventing flares and treating the symptoms when they occur.

GlaxoSmithKline came up with first ever targeted therapy for the treatment of SLE, with the introduction of Benlysta Before the approval of Benlysta, the SLE market was solely dominated by off-label therapies, used in the management of SLE i.e., Corticosteroids, NSAIDs, anti-malarials, biologics (mainly, rituximab) and immunosuppressants, and hence the total market size of SLE, estimated in our report, is inclusive of these off-label therapies. Corticosteroids continue to be the mainstay in the management of SLE, particularly when an immediate aid is required. The most commonly used corticosteroids are: prednisolone and prednisone.

New treatments, more specific to SLE and less immunosuppressive, are being explored to tackle autoimmunity. With deeper understanding and higher knowledge of pathophysiology of SLE, it is expected that the upcoming treatment therapies might provide a cure to the disease. It will probably involve combination of therapies that are addressed not only to eradicate the aberrant auto-destructive immune system but also to target 'specific' auto-antigens.

Systemic Lupus Erythematosus companies covered

1. AstraZeneca
2. ImmuPharma
3. Merck KgaA
4. Neovacs
5. Eli Lilly and Company
And many others

Systemic Lupus Erythematosus Drugs covered

1. Anifrolumab
2. Lupuzor
3. Atacicept
4. IFN? KINOID
5. Baricitinib
And many others

Table of contents

1. Report Introduction
2. Systemic Lupus Erythematosus Market Overview at a Glance
3. Systemic Lupus Erythematosus Disease Background and Overview
4. Systemic Lupus Erythematosus Epidemiology and Patient Population
5. Systemic Lupus Erythematosus Epidemiology
5.1. United States
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.5. France
5.6. Italy
5.7. Spain
5.8. United Kingdom
5.9. Japan
6. Current Treatment & Medical practices
7. Unmet Needs of the Systemic Lupus Erythematosus
8. Marketed Therapies
8.1. Drug A: Company 1
8.2. Drug B: Company 2
9. Systemic Lupus Erythematosus Pipeline Therapies– At a glance
10. Systemic Lupus Erythematosus Key Cross Competition
11. Systemic Lupus Erythematosus Emerging Therapies
11.1. Drug C: Company 3
11.2. Drug D: Company 4
12. Systemic Lupus Erythematosus 7MM Market Analysis
13. Systemic Lupus Erythematosus : Country-Wise Market Analysis
13.2. EU-5
13.2.1. Germany
13.2.2. France
13.2.3. Italy
13.2.4. Spain
13.2.5. United Kingdom
13.3. Japan
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
18. DelveInsight Capabilities
19. Disclaimer

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Contact us:
Shruti Thakur
info@delveinsight.com
+919650213330
SOURCE DelveInsight